Centessa Pharmaceuticals plc announced the appointment of Patrick Yue, MD, to Centessa's management team as Senior Vice President of Clinical Development, Innovative Medicines. In this newly created role, Dr. Yue will primarily focus on select pipeline programs, including SerpinPC, MGX292 and orexin agonists. Prior to joining Centessa, Dr. Yue was Vice President of Clinical Science at Global Blood Therapeutics, where he oversaw four development programs, including voxelotor (Oxbryta) a treatment for sickle cell disease.

Dr. Yue has spent 12 years in the biotech/pharmaceutical industry, taking on roles of increasing responsibility at Gilead, Portola, Alexion and Pfizer. Prior to joining the industry, Dr. Yue completed his medical internship and residency at Beth Israel Deaconess Medical Center and received specialty training in cardiovascular medicine at Stanford University School of Medicine. Dr. Yue holds a BS in Biology and Chemistry from the California Institute of Technology (Caltech) and an MD from the Washington University School of Medicine.